US Stock MarketDetailed Quotes
HALO Halozyme Therapeutics
- 48.815
- +3.115+6.82%
Trading Nov 22 15:04 ET
6.21BMarket Cap16.16P/E (TTM)
49.320High46.300Low3.30MVolume48.930Open45.700Pre Close159.00MTurnover2.62%Turnover Ratio23.25P/E (Static)127.23MShares65.53352wk High13.72P/B6.15BFloat Cap33.15052wk Low--Dividend TTM125.89MShs Float65.533Historical High--Div YieldTTM6.61%Amplitude1.410Historical Low48.218Avg Price1Lot Size
Halozyme Therapeutics Key Stats
EPS
According to the latest financial report of Halozyme Therapeutics, the latest earnings per share (TTM) for the company is 1.05. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
FCF
Interested in knowing about Halozyme Therapeutics's free cash flow? The latest report shows it as 113.86M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Halozyme Therapeutics shows that the company's current ratio is 10.36, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Halozyme Therapeutics, the quick ratio is 8.75, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
ROE
Want to learn more about the financial health of Halozyme Therapeutics? The latest ROE figure is 36.92%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Halozyme Therapeutics, the total asset return on investment (ROA) is 6.70%.
Currency: USD
Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Halozyme Therapeutics's latest financial report to see how their gross margin is doing - currently at 82.96%.
Currency: USD
Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Halozyme Therapeutics, the net profit margin is 47.23%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data